reading pharmacology threads from 2024 and half of it aged badly
reading pharmacology threads from 2024 and half of it aged badly — a position I have arrived at slowly and would like tested. The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary. Started reading limitations sections first. It has changed how much weight I give to…
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
preclinical is not clinical and rodents are not small people
albumin binding is most of the half-life story
read the discussion section, that is where the honesty lives
mechanism explains a direction, not a magnitude
the peripheral and central stories are not in competition